Oruka Therapeutics general counsel sells $706k in shares

On October 20, 2026, Paul T. Quinlan, the General Counsel at Oruka Therapeutics, Inc., sold 9,000 shares of the company's common stock, totaling $706,734. The sales were conducted following a Rule 10b5-1 trading plan established on May 15, 2026, and occurred during a period of strong stock performance, with shares gaining a 189% return over the past year.

According to InvestingPro analysis, the stock appeared overvalued relative to its Fair Value estimate, ranking among companies on an overvalued list. Prior to these sales, Quinlan acquired 9,000 shares by exercising employee warrants at an exercise price of $7.80 per share, amounting to $70,200. These shares vested as 1/4 of the underlying shares on April 30, 2025, and as 1/48 of the underlying shares monthly from that date.

Following the stock sales, Quinlan held 29,995 shares of Oruka Therapeutics common stock. The company has recently reported positive results from its EVERLAST-A Phase 2a trial for the psoriasis treatment ORKA-001, with PASI 100 response rates increasing to 71.4% and PASI 90 rates rising to 87.3%. Oruka Therapeutics has also been rated an Overweight by Piper Sandler with a price target of $180 and a Buy rating from H.C.

Wainwright with a $120 price target, highlighting the strength of its drug pipeline. The company recently appointed Todd Edwards as its Chief Commercial Officer, bringing over 25 years of commercial leadership experience.